BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at JMP Securities Hematology & Oncology Summit

BioCryst to Present at JMP Securities Hematology & Oncology Summit

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET.

Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including oral factor D inhibitors BCX9930 and BCX10013, which are in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at .

BCRXW

Investor Contact:

John Bluth



Media Contact:

Catherine Collier Kyroulis



 



EN
05/12/2022

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business ...

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million —Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from pr...

June 27, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
BCRX BIOCRYST PHARMACEUTICALS INC.
06/25/25 June 25, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORL...

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI —Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients ...

June 16, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

ORLADEYO® (berotralstat) Approved in Colombia

ORLADEYO® (berotralstat) Approved in Colombia RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “Today’s announcement marks another important step toward bringing ORLADEYO to people living with HAE who are in need of new treatment options across the pan-Latin America region. Followin...

June 13, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European...

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major European countries, providing ...

June 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch